We retrospectively identified all t(11;14) MM patients….The primary endpoint was OS measured from the time of MM diagnosis compared between Ven-treated patients and those who did not receive Ven....In univariable analyses, 1q amplification/gain was associated with inferior PFS (13 months [95% CI, 6.5-28 months]) vs 33 months [95% CI, 23 months-not reached/NR]; p = 0.04).

Median PFS in t(11;14) patients was 7.41 months vs 4 months in patients in the non-t(11;14) group (p=0.07). Further stratification based on gain of 1q revealed that patients with t(11;14) and concurrent gain of 1q (n=19; 39.5%) had significantly worse PFS than patients with t(11;14) alone (HR=5.4; 95% CI: 1.9-15.1; p<0.001) (Fig. 1A)...here we report that gain of 1q is associated with shorter response to venetoclax in MM, including patients with t(11;14)...